A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma
Purpose This prospective study aims to explore the benefit of cytokine-induced killer cell (CIK) treatment in hepatocellular carcinoma patients, which has not yet been thoroughly studied before. Methods From January 2004 to May 2009, 132 patients who were initially diagnosed with hepatocellular carc...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical immunology 2014-02, Vol.34 (2), p.194-203 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 203 |
|---|---|
| container_issue | 2 |
| container_start_page | 194 |
| container_title | Journal of clinical immunology |
| container_volume | 34 |
| creator | Yu, Xiaozhou Zhao, Hua Liu, Liang Cao, Shui Ren, Baozhu Zhang, Naining An, Xiumei Yu, Jinpu Li, Hui Ren, Xiubao |
| description | Purpose
This prospective study aims to explore the benefit of cytokine-induced killer cell (CIK) treatment in hepatocellular carcinoma patients, which has not yet been thoroughly studied before.
Methods
From January 2004 to May 2009, 132 patients who were initially diagnosed with hepatocellular carcinoma of Barcelona Clinic Liver Cancer (BCLC) stage A, B or C, Child–Pugh scores of A or B and without prior treatment were enrolled in the study. Patients were randomly assigned to either arm 1 (
n
= 66) to receive CIK treatment plus standard treatment, or arm 2 (
n
= 66) to receive standard treatment only. The primary end point was overall survival (OS) and the secondary endpoint was progression-free survival as evaluated by Kaplan–Meier analyses and treatment hazard ratios with the Cox proportional hazards model.
Results
The 1-year (OS: 74.2 % vs. 50.0 %, 95 % CI: 63.6–84.8 % vs. 37.8–62.2,
p
= 0.002), 2-year (OS: 53.0 % vs. 30.3 %, 95 % CI: 40.8–65.2 % vs. 19.1–41.5 %,
p
= 0.002), 3-year (OS: 42.4 % vs. 24.2 %, 95 % CI: 30.4–54.4 % vs. 13.8–34.6 %,
p
= 0.005) and median overall and progression-free survivals of arm 1 patients were significantly higher than those of arm 2. Therefore, in patients who are not suitable for surgery, significant benefit is obtained from CIK treatment. The main adverse effects of CIK included fever, allergy and headache pain.
Conclusions
Hepatocellular carcinoma patients who were not suitable for surgery demonstrate prolonged overall and progression-free survival from CIK treatment. |
| doi_str_mv | 10.1007/s10875-013-9976-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1534828570</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1534828570</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-111a55f12003ca425d83c6fa827bab89445a02baaca62fe5f7aa61acc8d8a81d3</originalsourceid><addsrcrecordid>eNp1kUtLxDAUhYMoOD5-gLuAGzfR3LRp06WIjwHBja7DnTR1OrbJmKSL8debMi5EcJXF_c7hhI-QC-DXwHl9E4GrWjIOBWuaumL8gCxA1gUTshGHZMFFDayBUhyTkxg3nPOiEnJB_C0N6Fo_9l-2pds1RkuXSxrT1O6o7yhOyQ_-3U-Rml3yH72zrHftZDL90Q-DDdTYYYi0dzQFi2m0Ls3Btd1i8vNtwsxgML3zI56Row6HaM9_3lPy9nD_evfEnl8el3e3z8yUIBMDAJSyA5F3GiyFbFVhqg6VqFe4Uk1ZSuRihWiwEp2VXY1YARqjWoUK2uKUXO17t8F_TjYmPfZxXoPO5s9okEWphJI1z-jlH3Tjp-Dyukxx0VSFUGWmYE-Z4GMMttPb0I8Ydhq4nhXovQKdFehZgZ6bxT4TM-vebfjV_G_oGzr-irM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1502963284</pqid></control><display><type>article</type><title>A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma</title><source>SpringerLink Journals - AutoHoldings</source><creator>Yu, Xiaozhou ; Zhao, Hua ; Liu, Liang ; Cao, Shui ; Ren, Baozhu ; Zhang, Naining ; An, Xiumei ; Yu, Jinpu ; Li, Hui ; Ren, Xiubao</creator><creatorcontrib>Yu, Xiaozhou ; Zhao, Hua ; Liu, Liang ; Cao, Shui ; Ren, Baozhu ; Zhang, Naining ; An, Xiumei ; Yu, Jinpu ; Li, Hui ; Ren, Xiubao</creatorcontrib><description>Purpose
This prospective study aims to explore the benefit of cytokine-induced killer cell (CIK) treatment in hepatocellular carcinoma patients, which has not yet been thoroughly studied before.
Methods
From January 2004 to May 2009, 132 patients who were initially diagnosed with hepatocellular carcinoma of Barcelona Clinic Liver Cancer (BCLC) stage A, B or C, Child–Pugh scores of A or B and without prior treatment were enrolled in the study. Patients were randomly assigned to either arm 1 (
n
= 66) to receive CIK treatment plus standard treatment, or arm 2 (
n
= 66) to receive standard treatment only. The primary end point was overall survival (OS) and the secondary endpoint was progression-free survival as evaluated by Kaplan–Meier analyses and treatment hazard ratios with the Cox proportional hazards model.
Results
The 1-year (OS: 74.2 % vs. 50.0 %, 95 % CI: 63.6–84.8 % vs. 37.8–62.2,
p
= 0.002), 2-year (OS: 53.0 % vs. 30.3 %, 95 % CI: 40.8–65.2 % vs. 19.1–41.5 %,
p
= 0.002), 3-year (OS: 42.4 % vs. 24.2 %, 95 % CI: 30.4–54.4 % vs. 13.8–34.6 %,
p
= 0.005) and median overall and progression-free survivals of arm 1 patients were significantly higher than those of arm 2. Therefore, in patients who are not suitable for surgery, significant benefit is obtained from CIK treatment. The main adverse effects of CIK included fever, allergy and headache pain.
Conclusions
Hepatocellular carcinoma patients who were not suitable for surgery demonstrate prolonged overall and progression-free survival from CIK treatment.</description><identifier>ISSN: 0271-9142</identifier><identifier>EISSN: 1573-2592</identifier><identifier>DOI: 10.1007/s10875-013-9976-0</identifier><identifier>CODEN: JCIMDO</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Immunology ; Infectious Diseases ; Internal Medicine ; Medical Microbiology ; Original Research</subject><ispartof>Journal of clinical immunology, 2014-02, Vol.34 (2), p.194-203</ispartof><rights>Springer Science+Business Media New York 2013</rights><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-111a55f12003ca425d83c6fa827bab89445a02baaca62fe5f7aa61acc8d8a81d3</citedby><cites>FETCH-LOGICAL-c415t-111a55f12003ca425d83c6fa827bab89445a02baaca62fe5f7aa61acc8d8a81d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10875-013-9976-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10875-013-9976-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Yu, Xiaozhou</creatorcontrib><creatorcontrib>Zhao, Hua</creatorcontrib><creatorcontrib>Liu, Liang</creatorcontrib><creatorcontrib>Cao, Shui</creatorcontrib><creatorcontrib>Ren, Baozhu</creatorcontrib><creatorcontrib>Zhang, Naining</creatorcontrib><creatorcontrib>An, Xiumei</creatorcontrib><creatorcontrib>Yu, Jinpu</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Ren, Xiubao</creatorcontrib><title>A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma</title><title>Journal of clinical immunology</title><addtitle>J Clin Immunol</addtitle><description>Purpose
This prospective study aims to explore the benefit of cytokine-induced killer cell (CIK) treatment in hepatocellular carcinoma patients, which has not yet been thoroughly studied before.
Methods
From January 2004 to May 2009, 132 patients who were initially diagnosed with hepatocellular carcinoma of Barcelona Clinic Liver Cancer (BCLC) stage A, B or C, Child–Pugh scores of A or B and without prior treatment were enrolled in the study. Patients were randomly assigned to either arm 1 (
n
= 66) to receive CIK treatment plus standard treatment, or arm 2 (
n
= 66) to receive standard treatment only. The primary end point was overall survival (OS) and the secondary endpoint was progression-free survival as evaluated by Kaplan–Meier analyses and treatment hazard ratios with the Cox proportional hazards model.
Results
The 1-year (OS: 74.2 % vs. 50.0 %, 95 % CI: 63.6–84.8 % vs. 37.8–62.2,
p
= 0.002), 2-year (OS: 53.0 % vs. 30.3 %, 95 % CI: 40.8–65.2 % vs. 19.1–41.5 %,
p
= 0.002), 3-year (OS: 42.4 % vs. 24.2 %, 95 % CI: 30.4–54.4 % vs. 13.8–34.6 %,
p
= 0.005) and median overall and progression-free survivals of arm 1 patients were significantly higher than those of arm 2. Therefore, in patients who are not suitable for surgery, significant benefit is obtained from CIK treatment. The main adverse effects of CIK included fever, allergy and headache pain.
Conclusions
Hepatocellular carcinoma patients who were not suitable for surgery demonstrate prolonged overall and progression-free survival from CIK treatment.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Medical Microbiology</subject><subject>Original Research</subject><issn>0271-9142</issn><issn>1573-2592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kUtLxDAUhYMoOD5-gLuAGzfR3LRp06WIjwHBja7DnTR1OrbJmKSL8debMi5EcJXF_c7hhI-QC-DXwHl9E4GrWjIOBWuaumL8gCxA1gUTshGHZMFFDayBUhyTkxg3nPOiEnJB_C0N6Fo_9l-2pds1RkuXSxrT1O6o7yhOyQ_-3U-Rml3yH72zrHftZDL90Q-DDdTYYYi0dzQFi2m0Ls3Btd1i8vNtwsxgML3zI56Row6HaM9_3lPy9nD_evfEnl8el3e3z8yUIBMDAJSyA5F3GiyFbFVhqg6VqFe4Uk1ZSuRihWiwEp2VXY1YARqjWoUK2uKUXO17t8F_TjYmPfZxXoPO5s9okEWphJI1z-jlH3Tjp-Dyukxx0VSFUGWmYE-Z4GMMttPb0I8Ydhq4nhXovQKdFehZgZ6bxT4TM-vebfjV_G_oGzr-irM</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Yu, Xiaozhou</creator><creator>Zhao, Hua</creator><creator>Liu, Liang</creator><creator>Cao, Shui</creator><creator>Ren, Baozhu</creator><creator>Zhang, Naining</creator><creator>An, Xiumei</creator><creator>Yu, Jinpu</creator><creator>Li, Hui</creator><creator>Ren, Xiubao</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20140201</creationdate><title>A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma</title><author>Yu, Xiaozhou ; Zhao, Hua ; Liu, Liang ; Cao, Shui ; Ren, Baozhu ; Zhang, Naining ; An, Xiumei ; Yu, Jinpu ; Li, Hui ; Ren, Xiubao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-111a55f12003ca425d83c6fa827bab89445a02baaca62fe5f7aa61acc8d8a81d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Immunology</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Medical Microbiology</topic><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Xiaozhou</creatorcontrib><creatorcontrib>Zhao, Hua</creatorcontrib><creatorcontrib>Liu, Liang</creatorcontrib><creatorcontrib>Cao, Shui</creatorcontrib><creatorcontrib>Ren, Baozhu</creatorcontrib><creatorcontrib>Zhang, Naining</creatorcontrib><creatorcontrib>An, Xiumei</creatorcontrib><creatorcontrib>Yu, Jinpu</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Ren, Xiubao</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Xiaozhou</au><au>Zhao, Hua</au><au>Liu, Liang</au><au>Cao, Shui</au><au>Ren, Baozhu</au><au>Zhang, Naining</au><au>An, Xiumei</au><au>Yu, Jinpu</au><au>Li, Hui</au><au>Ren, Xiubao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma</atitle><jtitle>Journal of clinical immunology</jtitle><stitle>J Clin Immunol</stitle><date>2014-02-01</date><risdate>2014</risdate><volume>34</volume><issue>2</issue><spage>194</spage><epage>203</epage><pages>194-203</pages><issn>0271-9142</issn><eissn>1573-2592</eissn><coden>JCIMDO</coden><abstract>Purpose
This prospective study aims to explore the benefit of cytokine-induced killer cell (CIK) treatment in hepatocellular carcinoma patients, which has not yet been thoroughly studied before.
Methods
From January 2004 to May 2009, 132 patients who were initially diagnosed with hepatocellular carcinoma of Barcelona Clinic Liver Cancer (BCLC) stage A, B or C, Child–Pugh scores of A or B and without prior treatment were enrolled in the study. Patients were randomly assigned to either arm 1 (
n
= 66) to receive CIK treatment plus standard treatment, or arm 2 (
n
= 66) to receive standard treatment only. The primary end point was overall survival (OS) and the secondary endpoint was progression-free survival as evaluated by Kaplan–Meier analyses and treatment hazard ratios with the Cox proportional hazards model.
Results
The 1-year (OS: 74.2 % vs. 50.0 %, 95 % CI: 63.6–84.8 % vs. 37.8–62.2,
p
= 0.002), 2-year (OS: 53.0 % vs. 30.3 %, 95 % CI: 40.8–65.2 % vs. 19.1–41.5 %,
p
= 0.002), 3-year (OS: 42.4 % vs. 24.2 %, 95 % CI: 30.4–54.4 % vs. 13.8–34.6 %,
p
= 0.005) and median overall and progression-free survivals of arm 1 patients were significantly higher than those of arm 2. Therefore, in patients who are not suitable for surgery, significant benefit is obtained from CIK treatment. The main adverse effects of CIK included fever, allergy and headache pain.
Conclusions
Hepatocellular carcinoma patients who were not suitable for surgery demonstrate prolonged overall and progression-free survival from CIK treatment.</abstract><cop>Boston</cop><pub>Springer US</pub><doi>10.1007/s10875-013-9976-0</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-9142 |
| ispartof | Journal of clinical immunology, 2014-02, Vol.34 (2), p.194-203 |
| issn | 0271-9142 1573-2592 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1534828570 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Biomedical and Life Sciences Biomedicine Immunology Infectious Diseases Internal Medicine Medical Microbiology Original Research |
| title | A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A28%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomized%20phase%20II%20study%20of%20autologous%20cytokine-induced%20killer%20cells%20in%20treatment%20of%20hepatocelluar%20carcinoma&rft.jtitle=Journal%20of%20clinical%20immunology&rft.au=Yu,%20Xiaozhou&rft.date=2014-02-01&rft.volume=34&rft.issue=2&rft.spage=194&rft.epage=203&rft.pages=194-203&rft.issn=0271-9142&rft.eissn=1573-2592&rft.coden=JCIMDO&rft_id=info:doi/10.1007/s10875-013-9976-0&rft_dat=%3Cproquest_cross%3E1534828570%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1502963284&rft_id=info:pmid/&rfr_iscdi=true |